Pharmacology and clinical efficacy of cholinesterase inhibitors

Keyphrases

• Acetylcholinesterase Inhibitors (AChEI) 100%
• Activities of Daily Living 14%
• Adverse Effects 28%
• Alzheimer's Disease 57%
• Alzheimer's Disease Assessment Scale 14%
• Behavior Problems 14%
• Caregiver Input 14%
• Cholinesterase Inhibition 14%
• Clinical Efficacy 100%
• Clinical Trials 14%
• Clinician Interviews 14%
• Cognitive Deficits 14%
• Donepezil 42%
• Drug Efficacy 14%
• Hepatotoxicity 14%
• Interview-based 14%
• Metabolic Pathway 14%
• Metrifonate 42%
• Once-daily 14%
• Pharmacokinetic Differences 14%
• Pharmacology 100%
• Rivastigmine 14%
• Tacrine 42%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 28%
• Alzheimer's Disease 71%
• Cholinesterase 14%
• Cholinesterase Inhibitor 100%
• Clinical Trial 14%
• Cognitive Defect 14%
• Donepezil 42%
• Hepatotoxicity 14%
• Metrifonate 42%
• Pharmacokinetics 14%
• Problem Behavior 14%
• Rivastigmine 14%
• Tacrine 42%